JP7168551B2 - 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体 - Google Patents

免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体 Download PDF

Info

Publication number
JP7168551B2
JP7168551B2 JP2019500377A JP2019500377A JP7168551B2 JP 7168551 B2 JP7168551 B2 JP 7168551B2 JP 2019500377 A JP2019500377 A JP 2019500377A JP 2019500377 A JP2019500377 A JP 2019500377A JP 7168551 B2 JP7168551 B2 JP 7168551B2
Authority
JP
Japan
Prior art keywords
chloro
benzyl
oxy
methyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524705A5 (OSRAM
JP2019524705A (ja
Inventor
カプ－スン・イェウン
キャサリン・エイ・グラント－ヤング
ジュリアン・ジュー
マーク・ジー・ソールニアー
デイビッド・ビー・フレンネソン
チャオシン・メン
ポール・マイケル・スコラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019524705A publication Critical patent/JP2019524705A/ja
Publication of JP2019524705A5 publication Critical patent/JP2019524705A5/ja
Application granted granted Critical
Publication of JP7168551B2 publication Critical patent/JP7168551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019500377A 2016-07-08 2017-07-05 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体 Active JP7168551B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359971P 2016-07-08 2016-07-08
US62/359,971 2016-07-08
PCT/US2017/040663 WO2018009505A1 (en) 2016-07-08 2017-07-05 1,3-dihydroxy-phenyl derivatives useful as immunomodulators

Publications (3)

Publication Number Publication Date
JP2019524705A JP2019524705A (ja) 2019-09-05
JP2019524705A5 JP2019524705A5 (OSRAM) 2020-08-13
JP7168551B2 true JP7168551B2 (ja) 2022-11-09

Family

ID=59351131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500377A Active JP7168551B2 (ja) 2016-07-08 2017-07-05 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体

Country Status (15)

Country Link
US (1) US10590105B2 (OSRAM)
EP (1) EP3481815B1 (OSRAM)
JP (1) JP7168551B2 (OSRAM)
KR (1) KR102491992B1 (OSRAM)
CN (1) CN109689640B (OSRAM)
AU (1) AU2017292758A1 (OSRAM)
BR (1) BR112019000247A2 (OSRAM)
CA (1) CA3029991A1 (OSRAM)
EA (1) EA201990221A1 (OSRAM)
ES (1) ES2895066T3 (OSRAM)
IL (1) IL264092A (OSRAM)
MA (1) MA45591A (OSRAM)
MX (1) MX2019000123A (OSRAM)
SG (1) SG11201900077QA (OSRAM)
WO (1) WO2018009505A1 (OSRAM)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
BR112019007450A2 (pt) 2016-10-14 2020-07-07 Precision Biosciences, Inc. meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b
CN110072860B (zh) 2016-12-20 2022-09-02 百时美施贵宝公司 可用作免疫调节剂的化合物
AU2017384900B2 (en) 2016-12-28 2020-12-10 GC Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
KR20190133714A (ko) 2017-03-27 2019-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 치환된 이소퀴놀린 유도체
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111655732B (zh) 2017-11-14 2023-09-12 Gc细胞治疗 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
ES2998139T3 (en) 2018-01-23 2025-02-19 Bristol Myers Squibb Co 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. INDANAMINE AS PD-L1 ANTAGONISTS
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11578054B2 (en) 2018-03-01 2023-02-14 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN109305934A (zh) * 2018-08-07 2019-02-05 成都海博锐药业有限公司 苯醚类衍生物及可药用盐、医药上的用途
CN110872275A (zh) * 2018-08-31 2020-03-10 深圳微芯生物科技股份有限公司 作为免疫调节剂的联苯化合物及其用途
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
AU2019373702A1 (en) 2018-11-02 2021-06-24 Shanghai Maxinovel Pharmaceuticals Co., Ltd. Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
CN112313220B (zh) * 2019-02-21 2023-11-03 厦门宝太生物科技股份有限公司 Pd-l1拮抗剂化合物
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US20220168268A1 (en) 2019-03-22 2022-06-02 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same
EP3946625A1 (en) 2019-03-28 2022-02-09 Bristol-Myers Squibb Company Methods of treating tumor
JP2022526960A (ja) 2019-03-28 2022-05-27 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置する方法
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
MX2021013819A (es) 2019-05-15 2022-02-10 Chemocentryx Inc Compuestos de triarilo para el tratamiento de enfermedades asociadas a pd-l1.
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
EP3980413B1 (en) * 2019-06-07 2023-07-19 Janssen Sciences Ireland Unlimited Company Heterocyclic immunomodulators as pdl1 checkpoint inhibitor
CA3140588A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
BR112021023750A2 (pt) 2019-06-20 2022-01-11 Chemocentryx Inc Compostos para tratamento de doenças pd-l1
MX2022000318A (es) 2019-07-10 2022-02-10 Chemocentryx Inc Indanos como inhibidores de pd-l1.
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN112457308B (zh) * 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
BR112022004316A2 (pt) 2019-09-22 2022-06-21 Bristol Myers Squibb Co Caracterização espacial quantitativa para terapia de antagonista lag-3
CN112574183B (zh) * 2019-09-29 2022-07-08 南京华威医药科技集团有限公司 一种pd-1抑制剂及其制备方法和用途
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN114585359B (zh) 2019-10-16 2025-08-12 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
MX2022004450A (es) 2019-10-16 2022-05-03 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
MX2022008016A (es) * 2019-12-26 2022-07-27 Adlai Nortye Biopharma Co Ltd Compuesto antagonista de pd-l1.
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
CN111333629B (zh) * 2020-04-10 2021-03-05 颜建发 苯基-1h-吡唑类衍生物及其在抗肿瘤药物中的应用
IL297908A (en) 2020-05-05 2023-01-01 Teon Therapeutics Inc Cannabinoid receptor type 2 (cb2) modulators and uses thereof
MX2023002332A (es) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
WO2022052926A1 (zh) 2020-09-09 2022-03-17 广州再极医药科技有限公司 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
AU2022291381B2 (en) 2021-06-11 2025-04-24 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
CN119731651A (zh) 2022-04-08 2025-03-28 百时美施贵宝公司 三级淋巴结构的机器学习标识、分类和量化
EP4554943A1 (en) 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN118265699A (zh) * 2022-10-26 2024-06-28 西安新通药物研究股份有限公司 一种非对称性联苯衍生物及其制备方法与医药用途
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN116332821B (zh) * 2023-04-06 2025-02-07 杭州国瑞生物科技有限公司 一种5-(2-氟苯基)-1h-吡咯-3-甲腈的制备方法
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP2018534282A (ja) 2015-10-15 2018-11-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
TW200815377A (en) * 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP2018534282A (ja) 2015-10-15 2018-11-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物

Also Published As

Publication number Publication date
EP3481815A1 (en) 2019-05-15
WO2018009505A1 (en) 2018-01-11
SG11201900077QA (en) 2019-02-27
KR102491992B1 (ko) 2023-01-25
BR112019000247A2 (pt) 2019-04-16
IL264092A (en) 2019-02-28
CN109689640B (zh) 2022-01-04
JP2019524705A (ja) 2019-09-05
KR20190026859A (ko) 2019-03-13
ES2895066T3 (es) 2022-02-17
US20190185450A1 (en) 2019-06-20
CN109689640A (zh) 2019-04-26
CA3029991A1 (en) 2018-01-11
AU2017292758A1 (en) 2019-02-21
MX2019000123A (es) 2019-04-01
MA45591A (fr) 2021-05-26
EA201990221A1 (ru) 2019-06-28
EP3481815B1 (en) 2021-09-29
US10590105B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
JP7168551B2 (ja) 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体
US11046675B2 (en) Substituted isoquionline derivatives as immunomudulators
KR102758923B1 (ko) 면역조정제로서 유용한 화합물
KR102738303B1 (ko) 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물
KR102599339B1 (ko) 면역조정제로서 유용한 화합물
KR102276644B1 (ko) 면역조절제로서 유용한 화합물
JP6556755B2 (ja) 免疫調節剤として有用な化合物
JP7642625B2 (ja) 免疫調節剤として有用な化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221027

R150 Certificate of patent or registration of utility model

Ref document number: 7168551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250